Lynozyfic could have an edge over rival BCMA-targeting bispecifics.
ApexOnco Front Page
Recent articles
3 July 2025
Zegfrovy is approved in a best-case setting, but Dizal has no US presence.
26 June 2025
The company reckons its immunotherapy could improve on Keytruda.
26 June 2025
First-in-human studies include a new pan-KRAS inhibitor and CDK2/4 degrader.
25 June 2025
“We need all the capital we can get our hands on," the company states.
24 June 2025
Zidesamtinib is having a hard time catching up with Ibtrozi's line-agnostic approval.